ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Proteostasis Therapeutics Inc

Proteostasis Therapeutics Inc (PTI)

1.11
0.00
(0.00%)
Closed March 29 04:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.11
Bid
1.12
Ask
1.14
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.11
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
10,856,000
Dividend Yield
-
PE Ratio
-0.32
Earnings Per Share (EPS)
-5.84
Revenue
1.95M
Net Profit
-63.41M

About Proteostasis Therapeutics Inc

Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of ... Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970

PTI Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

PTI Discussion

View Posts
BooDog BooDog 1 year ago
We were incorporated in Delaware on December 13, 2006 under the name Proteoguard, Inc. and subsequently changed our name to Proteostasis Therapeutics, Inc. on September 17, 2007. On December 22, 2020, we effected a reverse merger, pursuant to which a wholly-owned subsidiary of ours merged with and into Yumanity, Inc. (formerly Yumanity Therapeutics, Inc.), or Yumanity, with Yumanity surviving as a wholly-owned subsidiary of ours. On December 22, 2020, we changed our name from Proteostasis Therapeutics, Inc. to Yumanity Therapeutics, Inc. On December 16, 2022, we effected a reverse merger, pursuant to which a wholly-owned subsidiary of ours merged with and into Kineta, Inc., or Kineta, with Kineta surviving as a wholly-owned subsidiary of ours (such transaction, the β€œMerger”). On December 16, 2022, we changed our name from Yumanity Therapeutics, Inc. to Kineta, Inc. Our principal executive offices are located at 219 Terry Ave. N., Suite 300, Seattle, Washington 98109. Our telephone number is (206) 378-0400. Our website address is https://kinetabio.com. Information contained on our website or connected thereto does not constitute part of, and is not incorporated by reference into, this prospectus or the registration statement of which it forms a part.


https://www.sec.gov/Archives/edgar/data/1445283/000119312523019180/d437839d424b4.htm

I was wondering why PTI wasn't loading. It's now KA.

KA daily
πŸ‘οΈ0
hotmeat hotmeat 3 years ago
πŸ‘οΈ0
Tdeank1 Tdeank1 3 years ago
Stalker
πŸ‘οΈ0
hotmeat hotmeat 3 years ago
Hey moron...couldnt give a rats arse what you think so save your commentary and just slither off already. You call me stalker even tho youre the one doing it. What a dumbass!
πŸ‘οΈ0
Tdeank1 Tdeank1 3 years ago
Stalker
πŸ‘οΈ0
hotmeat hotmeat 3 years ago
Said the poof who keeps responding to my posts to other people....shit for brains.......
πŸ‘οΈ0
Tdeank1 Tdeank1 3 years ago
Stalker
πŸ‘οΈ0
hotmeat hotmeat 3 years ago
It's YOU who keeps responding to my posts on the COOP board, not the other way around jackass.

What a fukin clown. LOLOL

πŸ‘οΈ0
Tdeank1 Tdeank1 3 years ago
Ahhh, I see you will move on from constantly attacking them to stalking me....wonderful life
πŸ‘οΈ0
hotmeat hotmeat 3 years ago
In case you haven't noticed I have long moved on to other stocks from which I've benefitted greatly and will continue to in the coming months.

I continue to visit the COOP board because I still own all my Newco stock that I received in 2012.

I respond to the Escrow nonsense because I can, same as YOU DO, so I find your question to be foolish.

Was that clear enough you deluded assclown!?!!

πŸ‘οΈ0
nycbroker1 nycbroker1 3 years ago
Much better plays out there
πŸ‘οΈ0
MrMoonBucks MrMoonBucks 3 years ago
Do ur thing
πŸ‘οΈ0
nycbroker1 nycbroker1 3 years ago
I’ll buy back cheaper if the technicals say it’s time to buy
πŸ‘οΈ0
nycbroker1 nycbroker1 3 years ago
LoL. Ok.
πŸ‘οΈ0
MrMoonBucks MrMoonBucks 3 years ago
I held

Boss shit,

1.50+ next week and I’m gucci mane
πŸ‘οΈ0
nycbroker1 nycbroker1 3 years ago
I sold this morning for profit
πŸ‘οΈ0
MrMoonBucks MrMoonBucks 3 years ago
Dilution my nigga.

This shit dead let’s stay on stock twit...
πŸ‘οΈ0
nycbroker1 nycbroker1 3 years ago
Colton?
πŸ‘οΈ0
MrMoonBucks MrMoonBucks 3 years ago
3 months is too much. Colton from merger coming dec 16th. out by then safest strategy imo
πŸ‘οΈ0
MrMoonBucks MrMoonBucks 3 years ago
Starter here at 1.08. Hoping for sub 1’s to avg down. Looks good to fill 4.35 gap.
πŸ‘οΈ0
FullDisclosureEsq FullDisclosureEsq 3 years ago
Just started a position in PTI and can't wait to see what develops in the next 2-3 months. My research shows analysts have a median target of 4.00, with a high estimate of 8.00 and a low estimate of 2.00. I'm thinking closer to $8 with the recent collaboration with Yumanity.
πŸ‘οΈ0
jozac jozac 4 years ago
holding this-buying TNEN
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
nice bottom here http://www.stockta.com/cgi-bin/analysis.pl?symb=PTI&cobrand=&mode=stock
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Published: Aug 24, 2020

Combined companies to leverage their common scientific expertise in protein misfolding
Focus on Yumanity's lead clinical program in Parkinson's disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders
Companies to host joint conference call today, August 24, at 8:00 AM ET
BOSTON, Aug. 24, 2020 /PRNewswire/ -- Yumanity Therapeutics and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that the companies have entered into a definitive merger agreement. The combined company, operating under the name Yumanity Therapeutics, Inc., will leverage a common scientific expertise in the area of protein misfolding to advance Yumanity's pipeline of innovative, disease-modifying programs for neurodegenerative diseases.

Yumanity's first clinical-stage product candidate, YTX-7739, is currently in Phase 1 clinical development for the treatment and disease modification of Parkinson's disease. Yumanity is also advancing several additional candidates for other neurodegenerative disorders, including dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and frontotemporal lobar dementia (FTLD).

"The combination of PTI and Yumanity brings together two technologies rooted in a shared scientific legacy of protein misfolding as the basis of disease, as well as capabilities and resources that offer shareholders a broad platform for value creation," commented Meenu Chhabra, President and Chief Executive Officer of PTI. "We believe the combined company is well-positioned to advance multiple programs into and through the clinic, including Yumanity's lead candidate YTX-7739, currently in Phase 1 trials for the treatment of Parkinson's disease. We are excited to be working with Yumanity's management team and leading investors to complete the merger."

Yumanity has raised more than $100 million from leading investors that include Alexandria Venture Investments, Biogen, Fidelity, Merck, Pfizer, Redmile Group, and Sanofi Ventures. The Company also recently entered into a strategic research collaboration with Merck (known as MSD outside the United States and Canada) for the discovery and development of novel agents for the treatment of ALS and FTLD with Yumanity eligible to receive future payments totaling approximately $500 million in addition to royalties on the net sales of any marketed products. Upon the anticipated closing of the merger between PTI and Yumanity, Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity, will become President, Chief Executive Officer and Director of the combined company.

"Yumanity's state-of-the-art R&D efforts and deep insights into new potential targets to treat neurodegenerative diseases places us on a rapid trajectory toward our goal of revolutionizing the treatment of these disorders. Our merger with PTI should enable the combined company to grow faster, deliver potential therapies to patients more quickly and create sustainable shareholder value well beyond what either of us would achieve separately," said Dr. Peters. "We have made significant clinical and business progress over the past several months, including our recent strategic research collaboration with Merck and our Series C financing. This merger also ensures that we have access to the additional capital we will need to advance our pipeline of disease-modifying therapies."

"Today's announcement brings together two organizations that share a common scientific heritage in the science of protein misfolding and brings that science one step closer to novel solutions for patients suffering from the debilitation of neurodegenerative diseases," said Tony Coles, M.D., Chairman and Co-founder of Yumanity Therapeutics. "We look forward to continuing this important clinical work on behalf of patients as we make this transition to becoming a public company."

Proteostasis' Cystic Fibrosis (CF) Program Update

PTI also announced today that it is pursuing a strategic transaction related to its proprietary CFTR modulators. PTI plans to share proceeds from any monetization of its CF assets through contingent value rights (CVR). PTI stockholders of record as of the close of the merger would receive a portion of any upfront payment and CVRs entitling the holders to all net proceeds from any future milestones derived from the grant, sale or transfer of rights by PTI through a transaction completed from now until the closing of the merger. PTI stockholders of record would also be entitled to a portion of any net proceeds from a transaction completed within nine months of the closing of merger. In addition to the merger agreement, a form of the CVR agreement outlining the mechanism for distributing of any such proceeds to legacy PTI holders will be filed with the U.S. Securities and Exchange Commission on Form 8-K.

PTI's CFTR modulators are currently being studied as part of the CHOICES development program. 502 subjects have completed enrollment in the organoid portion of the study, with data expected in the fourth quarter of 2020.

"We believe that our CF drug candidates have the highest probability of reaching patients in the hands of a pharmaceutical company with global development and commercialization capabilities that shares our vision of empowering the global CF patient community with more treatment options is realized," said Ms. Chhabra. "It has been an honor to serve the CF community in the fight to bring new treatment options to patients and their families."

About the Proposed Merger

Under the terms of the merger agreement, PTI will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of PTI common stock. Upon completion of the proposed acquisition, it is anticipated that existing PTI shareholders will own approximately 32.5% of the combined company and Yumanity shareholders will own approximately 67.5% of the combined company. The actual allocation will be subject to adjustment based on each company's outstanding equity ownership and Proteostasis' net cash balance at the time of closing of the merger. Following completion of the merger, the Yumanity Board of Directors will be expanded to nine persons to include the appointment of two current Proteostasis directors. The existing Yumanity Directors will continue to serve in their current positions and Dr. Coles will remain as chairperson.

The transaction has been approved by the boards of directors of both companies. The merger is expected to close in the fourth quarter of 2020, subject to customary closing conditions, including approval of the merger by the shareholders of PTI. The combined company is expected to trade on the NASDAQ Global Market under the ticker symbol YMTX.

In conjunction with this merger announcement, PTI has reduced its workforce by 79%. As of today, PTI has five full time employees supporting the proposed merger transaction and strategic efforts related to PTI's CF assets.

MTS Health Partners, L.P. is serving as the exclusive financial advisor to PTI and Cooley LLP is serving as legal counsel to PTI. Goodwin Procter LLP is serving as legal counsel for Yumanity.

Conference Call and Webcast

PTI and Yumanity will host a conference call and webcast to discuss the proposed transaction as well as Yumanity's drug discovery platform and development pipeline today, August 24 at 8:00 a.m. ET. The live webcast can be accessed on the Events & Presentations page of Yumanity's and PTI's websites or by dialing (844) 534-7315 (U.S.) or (574) 990-3007. The conference ID for the live call is 8351758. The conference call and webcast will include presentation slides that can be viewed through the webcast. An archived replay of the webcast will be available on the Yumanity and PTI websites.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit www.proteostasis.com.

About Yumanity Therapeutics, Inc.

Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform allows the Company to rapidly screen for disease-modifying therapies to overcome toxicity of misfolded proteins in neurogenerative diseases. Yumanity's growing pipeline consists of additional programs focused on Lewy body dementia, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease. For more information, please visit www.yumanity.com.

Additional Information about the Merger and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between Proteostasis Therapeutics, Inc. ("Proteostasis"), Yumanity Holdings, LLC ("Holdings") and Yumanity Therapeutics, Inc. ("Yumanity"). In connection with the proposed transaction, Proteostasis will file relevant materials with the Securities and Exchange Commission ("SEC"), including a registration statement on Form S-4 that will contain a prospectus and a proxy statement. Proteostasis will mail the proxy statement/prospectus to Proteostasis stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective. Investors and security holders of Proteostasis, Holdings and Yumanity are urged to read these materials when they become available because they will contain important information about Proteostasis, Holdings and Yumanity and the merger. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Proteostasis may file with the SEC or send to stockholders in connection with the proposed transaction. Investors and security holders may obtain free copies of the documents filed with the SEC on Proteostasis' website at www.proteostasis.com, by contacting Proteostasis' Investor Relations at (617) 225-0096 or the SEC's website at www.sec.gov. Investors and security holders are urged to read the proxy statement, prospectus and other relevant materials when they become available before making any voting or investment decision with respect to the merger.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Proteostasis and its directors and executive officers, Holdings and its directors and executive officers, and Yumanity and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Proteostasis in connection with the proposed transaction. Information about the executive officers and directors of Proteostasis is set forth in Proteostasis' Definitive Proxy Statement on Schedule 14A relating to the 2020 Annual Meeting of Stockholders, filed with the SEC on April 29, 2020. Other information regarding the interests of such individuals, as well as information regarding Holdings' directors and executive officers and Yumanity's directors and executive officers, will be set forth in the proxy statement/prospectus, which will be included in Proteostasis' registration on Form S-4 when it is filed with the SEC. You may obtain free copies of these documents as described in the preceding paragraph.

Proteostasis Forward-Looking Information

This press release contains forward-looking statements based upon Proteostasis', Holdings' and Yumanity's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements about the structure, timing and completion of the proposed merger; the combined company's listing on Nasdaq after closing of the proposed merger; the timing and results of planned preclinical studies or clinical trials of Yumanity's product candidates; the timing and status of partnership discussions for Proteostasis' CF program including any grant, sale or transfer of rights related to its proprietary CFTR modulators; the conditions under which payment under the CVRs will be met; expectations regarding the ownership structure of the combined company; each individual company's or the combined company's expected cash position at the closing of the proposed merger; the future operations of the combined company, including with respect to the continued development of Yumanity's clinical pipeline; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; the executive and board structure of the combined company; the location of the combined company's corporate headquarters; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; Yumanity having sufficient resources to advance its pipeline; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the risk that the conditions to the closing of the proposed merger are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed merger and the ability of each of Proteostasis, Holding and Yumanity to consummate the proposed merger; (iii) risks related to Proteostasis' ability to manage its operating expenses and its expenses associated with the proposed merger pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed merger; (v) the risk that as a result of adjustments to the exchange ratio, Proteostasis stockholders and Yumanity stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Proteostasis' common stock relative to the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; (ix) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance preclinical programs and clinical trials; (xi) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (xiii) the risk that the conditions to payment under the CVRs will be not be met and that the CVRs may otherwise never deliver any value to Proteostasis stockholders; and (xiv) risks associated with the possible failure to realize certain anticipated benefits of the proposed merger, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled "Risk Factors" in Proteostasis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the SEC, and in other filings that Proteostasis makes and will make with the SEC in connection with the proposed transactions, including the proxy statement/prospectus described above under "Additional Information about the Proposed Merger and Where to Find It." You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Proteostasis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



Proteostasis Contacts

Investors:
David Pitts / Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

Yumanity Contacts

Investors:
Burns McClellan, Inc.
Steve Klass
sklass@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006

PTI Logo (PRNewsfoto/Proteostasis Therapeutics, Inc.)

View original content to download multimedia:http://www.prnewswire.com/news-releases/yumanity-therapeutics-and-proteostasis-therapeutics-announce-merger-agreement-301116803.html

SOURCE Proteostasis Therapeutics, Inc.


Company Codes: NASDAQ-NMS:PTI
πŸ‘οΈ0
Wolf68 Wolf68 4 years ago
PTI ran today...news perhaps or progress on Covid-19 therapy
πŸ‘οΈ0
urge2surge urge2surge 4 years ago
Boards going to heat up me thinks...
πŸ‘οΈ0
herojima4 herojima4 4 years ago
this is good right??
http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-in-vitro-data-for-pti-129-as-potential-treatment-candidate-for-covid-19-301068350.html
πŸ‘οΈ0
Tdeank1 Tdeank1 4 years ago
Join our Proteostasis Therapeutics (PTI) facebook page...
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global
Healthcare Virtual Conference


BOSTON, May 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
(NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the
discovery and development of groundbreaking therapies to treat cystic fibrosis
(CF), today announced that Proteostasis management will present at the 2020
RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20,
2020 at 1:55 p.m. ET.

A live audio webcast of the RBC fireside chat will be available on the
Investor Events page in the Investors & Media section of the Company's
website, www.proteostasis.com. A replay of the webcast will be available on
the Company's website following the presentation.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing small molecule therapeutics to treat cystic fibrosis and other
diseases caused by dysfunctional protein processing. Headquartered in Boston,
MA, the Proteostasis Therapeutics team focuses on identifying therapies that
restore protein function. For more information, visit www.proteostasis.com.
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
Como on baby...$1.91 in premarket. Can we run this week and break $2.50?!?!
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
Just can't seem to get back above $2.00. Looking for a real breakout here.
πŸ‘οΈ0
herojima4 herojima4 4 years ago
here it is
πŸ‘οΈ0
fishon101 fishon101 4 years ago
$PTI getting ready to make a nice upward move!
πŸ‘οΈ0
Wolf68 Wolf68 4 years ago
That’s because no one is watching....except me, and something’s up
πŸ‘οΈ0
Clemdane Clemdane 4 years ago
We're up 29% and no one says anything?
πŸ‘οΈ0
fishon101 fishon101 4 years ago
Positive news would be great. I'm content knowing this will double and then some in the next year. PTI may end up challenging Vertex big time, which could be huge!
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
How about some positive news?
πŸ‘οΈ0
Tdeank1 Tdeank1 4 years ago
 join our slowly growing facebook page (proteostasis Therapeutics PTI) ?? http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-completion-scientific-advice
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
ZZzzzzzzz... did someone turn the lights out?
πŸ‘οΈ0
Tdeank1 Tdeank1 4 years ago
new facebook page ....proteostasis therapeutics (PTI)...join up

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $PTI Video Chart 03-13-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update - https://finance.yahoo.com/news/proteostasis-therapeutics-reports-fourth-quarter-203600118.html
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
PTI has lost all mojo. Sad.
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $PTI Video Chart 02-21-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Trons Trons 4 years ago
Whole market is down, which is holding this from pushing $2.50. We will get there soon
πŸ‘οΈ0
Trons Trons 4 years ago
Added - Big run coming here
πŸ‘οΈ0
Eurotradr Eurotradr 4 years ago
Nice start to the day. Hopefully closes up but currently not maintaining strength.
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $PTI Video Chart 02-20-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
BlackSnake1 BlackSnake1 4 years ago
Nice day for PTI!!!$$$
Loading every chance I get!
Some day before end of 2020, the news will hit and we will be at $20 + per share!!
πŸ‘οΈ0
Dallas-Cowboys Dallas-Cowboys 4 years ago
Seems like something is up
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock